Open AccessBrief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding
Author(s) -
Sean Brummel,
Taha E. Taha,
Konstantia Angelidou,
Friday Saidi,
Patience Atuhaire,
Dingase Dula,
Dhayendre Moodley,
Allen Matubu,
Gift Chareka,
Neetal Nevrekar,
Tichaona Vhembo,
Lee Fairlie,
Gerhard Theron,
Pendo Mlay,
Kathleen George,
Michael Basar,
Nahida Chakhtoura,
Renee Browning,
Mary Glenn Fowler,
Judith S. Currier,
Impaact Promise Bf,
FF Promise Study Team
Publication year - 2021
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002586
Subject(s) - breastfeeding , medicine , confidence interval , randomized controlled trial , adverse effect , hazard ratio , obstetrics , antiretroviral therapy , pediatrics , human immunodeficiency virus (hiv) , family medicine , viral load
IMPAACT PROMISE 1077BF/FF was a sequentially randomized study of pregnant and postpartum women living with HIV to investigate the efficacy and safety of antiretroviral therapy (ART). This Maternal Health Component investigated efficacy for the risk of developing AIDS or death; and safety among women randomized to continue ART (CTART: N = 289) or discontinue ART (N = 268) after cessation of breastfeeding or after confirmation of infant infection. No AIDS-defining illnesses were reported during follow-up in either arm. Adverse events of grade 3 or higher were more frequent in the CTART arm [hazard ratio = 1.78, 95% confidence interval: (1.05 to 3.02), P-value = 0.03]. The difference in adverse events in the 2 groups was mostly driven by moderate weight loss for women on the CTART arm.